List view / Grid view

Hit-to-Lead

 

Phico Therapeutics receives Translation Award to advance its SASPject™ PT4 aimed at Escherichia coli and Klebsiella pneumoniae towards clinical trials

9 March 2015 | By Phico Therapeutics

Phico Therapeutics, a biotechnology company developing a novel platform technology for a new generation of antibiotics aimed at overcoming antibacterial resistance, has been awarded a £2.25M Translation Award by the Wellcome Trust to develop its SASPject™ PT4 antibiotic, aimed at Escherichia coli and Klebsiella pneumoniae...

Send this to a friend